ABCG5 Genotype

If your cholesterol runs high and standard treatment is not bringing it down the way it should, your DNA may be part of the answer. ABCG5 (ATP-binding cassette transporter G5) is a gene that helps your body clear cholesterol and plant fats out of your blood through the liver and gut. When this gene carries certain inherited changes, that cleanup system stops working well, and cholesterol and plant sterols build up.

This test looks at your ABCG5 gene sequence. The result is a one-time read on whether you carry variants linked to sitosterolemia, an inherited disorder that pushes cholesterol and plant sterols high, or to a milder form that can mimic or worsen familial high cholesterol. Knowing this changes which treatments actually work for you.

What This Gene Actually Does

ABCG5 pairs up with a partner gene called ABCG8 to build a transporter, a kind of molecular pump that sits on the surface of cells in your liver and small intestine. That pump pushes cholesterol and plant sterols (compounds you eat in foods like vegetable oils, nuts, and seeds) back out into bile and into the gut so your body can get rid of them.

When the pump works normally, very little plant sterol ends up in your blood, and excess cholesterol gets routed out instead of stored. When ABCG5 variants reduce or disable the pump, the result is the opposite. Plant sterols accumulate in your blood and tissues, cholesterol clearance falls, and the conditions for early artery disease and other problems start building quietly.

Sitosterolemia: The Rare but Treatable Disease

The clearest reason this gene matters is a condition called sitosterolemia. When a person inherits two damaging ABCG5 variants (one from each parent), plant sterols in the blood rise to extreme levels. The condition causes yellowish fatty deposits in the skin and tendons (called xanthomas), low platelet counts and other blood abnormalities, and early atherosclerotic cardiovascular disease.

Sitosterolemia is rare, but it is consistently misdiagnosed as familial high cholesterol (familial hypercholesterolemia, or FH). In one Chinese pediatric case series, about two-thirds carried ABCG5 variants and the rest had variants in the partner gene ABCG8, though in European populations ABCG8 variants tend to predominate. A 21-year follow-up of one patient showed that even after diagnosis and treatment, plant sterol levels stayed elevated, which is one reason early identification matters.

The distinction matters because the treatment is different. Statins, the first-line drug for most high cholesterol, do not work well in sitosterolemia. A drug called ezetimibe (Zetia), which blocks sterol absorption in the gut, does. In a randomized trial of people with sitosterolemia, ezetimibe reduced sitosterol by about 21% and campesterol by about 24% compared with placebo.

Mimicking Familial High Cholesterol

You do not need two broken copies of ABCG5 for the gene to matter to your health. People with one damaging variant (heterozygous carriers) can show high cholesterol that looks like classic FH on a standard lipid panel.

In a study of about 3,000 people with clinical FH, a small percentage (around 2.4%) carried potentially harmful ABCG5 or ABCG8 variants. Their LDL cholesterol was lower than in people with classic LDL receptor mutations, so the picture is less severe but still meaningful. Their plant sterol levels were higher, with campesterol and sitosterol roughly twice as high in carriers compared to non-carriers.

In another study of nearly 500 people with FH, around 8% carried rare deleterious ABCG5 or ABCG8 mutations. Some carried these on top of a classic FH mutation, and that study found those people had significantly higher LDL cholesterol than people with only a classic FH mutation. Whether these effects truly stack is still debated, since a separate large analysis did not replicate that combined effect on LDL.

Early Coronary Artery Disease

A large genetic study covering more than a million people found that variants reducing sterol absorption alter non-HDL cholesterol levels and shift the risk of coronary artery disease. People who carry ABCG5 or ABCG8 loss-of-function variants have higher plant sterols and increased risk of coronary disease, beyond what their non-HDL cholesterol alone would predict. In that study, each 1 mmol/L increase in non-HDL cholesterol from ABCG5/8 variants carried roughly a 2-fold rise in coronary risk, compared to about 1.54-fold from other non-HDL-raising variants.

In one study of people who developed coronary disease before age 35 and had high LDL cholesterol, expanded genetic testing that included ABCG5 found a monogenic high-cholesterol diagnosis in about 38% of them. If you have heart disease at an unusually young age and your lipids are high, this gene is one of the places worth looking.

Gallstones and the Liver

ABCG5 also matters outside of cholesterol numbers. The same transporter that handles sterols in the blood also pushes cholesterol into bile. When this pumping is unusually active or unusually weak, gallstone risk shifts.

A meta-analysis pooling data across several studies found that the D19H variant in the partner gene ABCG8 is strongly linked to gallstone disease, with about 2.4-fold higher odds of gallstones in carriers. Population studies confirm this association, with about 1.9-fold higher risk in heterozygotes and 3.3-fold in homozygotes. The locus has also been linked to nonalcoholic fatty liver disease through its role in cholesterol and bile traffic.

Common Variants and Everyday Cholesterol

Most ABCG5 variants people carry are not the severe disease-causing kind. They are common polymorphisms that nudge cholesterol handling in small ways. In a small study of 91 people, those with the C/C genotype of one ABCG5 polymorphism had a bigger LDL cholesterol rise when they added eggs to their diet than people with other genotypes. Other common variants have been linked to small shifts in HDL cholesterol, insulin sensitivity, and how well the gut absorbs cholesterol from food.

These effects are subtle, but they help explain why two people can eat the same diet and end up with different cholesterol numbers, and why some people respond to dietary changes more dramatically than others.

One-Time Result, Lifetime Use

Your ABCG5 genotype does not change. You inherited it at conception and it will read the same whether you test today, next year, or thirty years from now. There is no value in retesting the gene itself. The value is in retesting the things downstream that respond to interventions.

If you carry a sitosterolemia-causing pair of variants, you should track LDL cholesterol and, where available, plant sterol levels (sitosterol, campesterol) at least annually, more often when starting or adjusting treatment. If you carry a single damaging variant, track LDL cholesterol on a standard schedule (yearly is reasonable for most adults paying attention to heart health, more often if levels are elevated or you are starting therapy). The genotype tells you the why. Lipid and sterol tracking tells you whether your plan is working.

What Can Make a Genetic Result Misleading

• Panel coverage: this test only detects the variants it is designed to detect. A negative result does not rule out every possible rare variant in ABCG5 that could affect your health, and it does not rule out variants in the partner gene ABCG8, which causes the same disease.
• Ancestry-specific frequencies: certain ABCG5 variants are more common in some populations. For example, p.Arg389His is a common pathogenic variant in Chinese patients with sitosterolemia. A panel built around variants common in one population may miss variants common in another.
• Variants of uncertain significance: sometimes a test flags a change in the gene whose clinical meaning is not yet known. This is not a definitive answer either way and may require updates as evidence grows.
• Direct-to-consumer reports are not the same: a finding on a consumer genetics service is not a clinical-grade result. A clinical confirmatory test should be done before changing treatment.

What an Unexpected Result Should Push You to Do

A positive result for one or two damaging ABCG5 variants is not a diagnosis on its own. It is a starting point for a workup. The right next steps depend on what the genotype is telling you.

If you carry two damaging variants, the workup should include plant sterol measurement (sitosterol, campesterol), a fasting lipid panel, a complete blood count to look for low platelets, a physical exam for xanthomas, and an evaluation for early atherosclerosis. A lipidologist or metabolic specialist should be involved, because the treatment plan (dietary restriction of plant sterols, ezetimibe, sometimes bile acid sequestrants) is meaningfully different from standard high-cholesterol care.

If you carry one damaging variant and your LDL cholesterol is elevated, the workup should focus on understanding the full lipid picture and whether any classic FH variants are also present. Carriers who have elevated LDL benefit from earlier and more aggressive lipid management. Ezetimibe tends to work especially well in this group: one observational study found ezetimibe combined with atorvastatin reduced LDL cholesterol more in people with ABCG5 or ABCG8 mutations than in people without them.

Because ABCG5 variants are inherited, anyone you share DNA with (parents, siblings, children) has a meaningful chance of carrying the same variant. Cascade testing of first-degree relatives is reasonable, especially if anyone in the family has early heart disease, unexplained high cholesterol, or unexplained low platelets. A genetic counselor can help work through who to test and how to share the information.

How This Compares to Other Lipid Genetics

Standard genetic panels for high cholesterol focus on three genes: LDLR, APOB, and PCSK9. Those panels catch classic familial hypercholesterolemia but miss the people whose high cholesterol comes from ABCG5 or ABCG8. In a Portuguese cohort of FH patients, about 2% of those who tested negative on classic FH panels carried a damaging variant in one of the FH-phenocopy genes (a group that includes ABCG5 and ABCG8 alongside others). Adding ABCG5 to a lipid genetics panel meaningfully expands what gets caught.

Plant sterol measurement (a blood test for sitosterol and campesterol) is the functional complement to ABCG5 genotyping. The gene tells you what you inherited. The sterol test tells you what is happening biochemically right now. Used together, they distinguish sitosterolemia from other forms of high cholesterol and confirm whether treatment is working.